Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

Laurence Krieger; Karim Fizazi; Neal Shore; Teuvo L. Tammela; Albertas Ulys; Egils Vjaters; Sergey Polyakov; Mindaugas Jievaltas; Murilo Luz; Boris Alekseev; Iris Kuss; Marie-Aude Le Berre; Oana Petrenciuc; Amir Snapir; Toni Sarapohja; Matthew R. Smith

Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

Laurence Krieger
, Karim Fizazi
, Neal Shore
, Teuvo L. Tammela
, Albertas Ulys
, Egils Vjaters
, Sergey Polyakov
, Mindaugas Jievaltas
, Murilo Luz
, Boris Alekseev
, Iris Kuss
, Marie-Aude Le Berre
, Oana Petrenciuc
, Amir Snapir
, Toni Sarapohja
, Matthew R. Smith

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	abs 27
Pages (from-to)	45-46
Journal	Asia-Pacific Journal of Clinical Oncology
Volume	16
Issue number	S9
Publication status	Published - Nov 2020
Externally published	Yes
Event	ANZUP 2020 Mini Annual Scientific Meeting: Australian and New Zealand Urogenital and Prostate Cancer Trials Group - Online Duration: 29 Nov 2020 → 30 Nov 2020 https://www.urotoday.com/conference-highlights/anzup-mini-asm-2020/anzup-2020-gu-malignancies-non-prostate/126258-anzup-mini-asm-2020-anzup-research-best-of-the-best.html https://www.usanz.org.au/news-updates/our-announcements/2020-announcements/november-2020/anzup-2020-mini-asm-register-now

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Field of Science*

3.2 Clinical medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

Cite this

Krieger, L., Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Le Berre, M.-A., Petrenciuc, O., Snapir, A., Sarapohja, T., & Smith, M. R. (2020). Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). Asia-Pacific Journal of Clinical Oncology, 16(S9), 45-46. Article abs 27. https://doi.org/10.1111/ajco.13541

@article{4dd7d4575a2b4a6aa798fa2b937f9bb1,

title = "Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)",

author = "Laurence Krieger and Karim Fizazi and Neal Shore and Tammela, \{Teuvo L.\} and Albertas Ulys and Egils Vjaters and Sergey Polyakov and Mindaugas Jievaltas and Murilo Luz and Boris Alekseev and Iris Kuss and \{Le Berre\}, Marie-Aude and Oana Petrenciuc and Amir Snapir and Toni Sarapohja and Smith, \{Matthew R.\}",

year = "2020",

month = nov,

language = "English",

volume = "16",

pages = "45--46",

journal = "Asia-Pacific Journal of Clinical Oncology",

issn = "1743-7555",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "S9",

note = "ANZUP 2020 Mini Annual Scientific Meeting : Australian and New Zealand Urogenital and Prostate Cancer Trials Group ; Conference date: 29-11-2020 Through 30-11-2020",

url = "https://www.urotoday.com/conference-highlights/anzup-mini-asm-2020/anzup-2020-gu-malignancies-non-prostate/126258-anzup-mini-asm-2020-anzup-research-best-of-the-best.html, https://www.usanz.org.au/news-updates/our-announcements/2020-announcements/november-2020/anzup-2020-mini-asm-register-now",

}

Krieger, L, Fizazi, K, Shore, N, Tammela, TL, Ulys, A, Vjaters, E, Polyakov, S, Jievaltas, M, Luz, M, Alekseev, B, Kuss, I, Le Berre, M-A, Petrenciuc, O, Snapir, A, Sarapohja, T & Smith, MR 2020, 'Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)', Asia-Pacific Journal of Clinical Oncology, vol. 16, no. S9, abs 27, pp. 45-46. <https://doi.org/10.1111/ajco.13541>

Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). / Krieger, Laurence; Fizazi, Karim; Shore, Neal et al.
In: Asia-Pacific Journal of Clinical Oncology, Vol. 16, No. S9, abs 27, 11.2020, p. 45-46.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Overall survival (OS) results of phase III ARAMIS study of darolutamide added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

AU - Krieger, Laurence

AU - Fizazi, Karim

AU - Shore, Neal

AU - Tammela, Teuvo L.

AU - Ulys, Albertas

AU - Vjaters, Egils

AU - Polyakov, Sergey

AU - Jievaltas, Mindaugas

AU - Luz, Murilo

AU - Alekseev, Boris

AU - Kuss, Iris

AU - Le Berre, Marie-Aude

AU - Petrenciuc, Oana

AU - Snapir, Amir

AU - Sarapohja, Toni

AU - Smith, Matthew R.

PY - 2020/11

Y1 - 2020/11

M3 - Meeting Abstract

SN - 1743-7555

VL - 16

SP - 45

EP - 46

JO - Asia-Pacific Journal of Clinical Oncology

JF - Asia-Pacific Journal of Clinical Oncology

IS - S9

M1 - abs 27

T2 - ANZUP 2020 Mini Annual Scientific Meeting

Y2 - 29 November 2020 through 30 November 2020

ER -